REHOVOT, Israel & PHILADELPHIA--(BUSINESS WIRE)--Rosetta Genomics, Ltd. (NASDAQ: ROSG), a leading developer of microRNA-based molecular diagnostics, announced today that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 7,592,441 to Rosetta Genomics. The patent relates to human microRNA miR-193b, as well as to complementary probes and vectors. This is the third patent issued to Rosetta Genomics by the USPTO. Recently it was shown that downregulation of miR-193b is associated with progression and invasion of human breast cancer (Li et al., Oncogene 2009).
